Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden
The price at which the RZV would be considered cost-effective varies greatly, highlighting the need to explore and consider parameter uncertainty in both analyses and procurement negotiations.
Authors
- Vibeke Sparring (ORCID: https://orcid.org/0000-0002-1248-8600)
- Katarina Widgren (ORCID: https://orcid.org/0000-0002-5713-0071)
- Emelie Heintz (ORCID: https://orcid.org/0000-0002-0715-7591)
- Shuang Hao (ORCID: https://orcid.org/0000-0002-2303-4532)
- Camilla Nystrand (ORCID: https://orcid.org/0000-0002-9866-1100)
Institutions
- Karolinska Institutet (SE)
- Department of Disease Control (TH)
- Stockholm Health Care Services (SE)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1007/s10198-025-01829-9
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00